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constipation, and erectile dysfunction. Initial spine magnetic reso-
nance imaging (MRI) showed a T2 hyperintense lesion in the cor-
nus medullaris, and spinal myelitis (SM) was rst suspected. After 
2 weeks, his neurologic symptoms expanded to right leg weak-
ness and sensory changes in the left leg. His initial laboratory test 
results were unremarkable, including complete blood count (CBC) 
(leukocytes 7.09×109/L, hemoglobin 16.1 g/dL, and platelets 206
×109/L), routine chemistry, and C-reactive protein level (3.2 mg/L). 
He was immediately admitted to the neurologic department and 
treated with steroids based on a cerebrospinal uid (CSF) study 
revealing an inammatory condition with lymphocytic pleocyto-
sis. Brain MRI showed no abnormality, and positron emission to-
mography–computed tomography revealed systemic inamma-
tory status involving the spinal cord, lungs, spleen, renal cortex, 
and prostate. Peripheral lymphadenopathy was not noted based 
on imaging studies. Among systemic autoimmune markers, anti-
nuclear antibody and anti-Ro/SSA antibody were detected. How-
ever, the patient did not meet the diagnostic criteria of Sjögren 
syndrome, namely symptoms lasting less than 3 months, no lym-
phocytic inltration on labial salivary gland biopsy, positive anti-
Ro antibody, positive Schirmer’s test result, and normal salivary ow. 
A bone marrow (BM) study for newly developed thrombocyto-
penia revealed a mature B-cell neoplasm, which was most likely 
diffuse large B-cell lymphoma (DLBCL). Microscopic examination 
of the BM revealed that the atypical cells (14.7% of all nucleated 
cells) were large, with irregular nuclear contours and cytoplasmic 
vacuolations (Fig. 1A). CBC ndings indicated thrombocytopenia 
(leukocytes 4.16×109/L, hemoglobin 15.6 g/dL, and platelets 59×
Dear Editor,
Primary bone marrow lymphoma (PBML) is a rare entity of non-
Hodgkin’s lymphoma (NHL) [1] with aggressive disease progres-
sion and poor prognosis. Although PBML has been documented 
in the literature since 1977, its diagnostic criteria or clinical fea-
tures are not clearly dened. With poor survival of less than 1 
month when not treated and less than 2 years when treated [2], 
timely and accurate diagnosis of PBML is essential. Atypical symp-
toms in the absence of a tumor mass and lymphadenopathy can 
make the diagnostic procedure extremely challenging, leading to 
missing the window of opportunity. Here, we present a patient 
with PBML exhibiting systemic inammatory symptoms mimick-
ing autoimmune disorders. 
A 53-year-old man visited the outpatient clinic of the neurosur-
gery department because of lower back pain that initiated 15 days 
ago. He presented with symptoms of spinal cord compression 
such as left leg weakness, urinary urgency, urge incontinence, 
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109/L). A peripheral blood smear test revealed leukoerythroblasto-
sis with 1% immature cells. The atypical population from the BM 
comprised CD19+ (kappa restricted), CD20+, cCD22+, cCD79a+, 
CD3-, CD7-, CD10-, CD34-, and TdT- in ow cytometry analysis 
(Navios, Beckman Coulter, CA, USA). Immunohistochemistry 
showed aggregation of CD20+ B cells, occupying 50% of the nu-
cleated cells. A complex BM karyotype was observed in a chro-
mosomal study (Fig. 1B). B-cell clonality was conrmed through 
the detection of immunoglobulin heavy chain and immunoglob-
ulin κ light chain gene rearrangements. Two days after the BM di-
agnosis was conrmed, the patient developed metabolic acidosis, 
hypotension, and respiratory failure, and he expired. 
We reviewed recent literature and documented clinical presen-
tations of primary BM DLBCL. The most common features of pri-
mary BM DLBCL are the lack of evidence of lymphoma involve-
ment of lymph nodes, elevated lactate dehydrogenase levels, ab-
sence of organomegaly, and clinical symptoms of fatigue and fe-
ver of unknown origin (Table 1). Our patient had no typical clini-
cal symptoms of lymphoma, but presented with SM, which has 
never been reported in the patients with this disease entity. All 
the previous cases of primary BM DLBCL involved cytopenia in at 
least one lineage at initial presentation. Our case did not involve 
cytopenia until SM progressed to systemic inammation when 
isolated mild thrombocytopenia appeared.
Primary BM DLBCL is a rare entity of extranodal NHL. The di-
agnostic challenges of this disease include overlapping features 
with those of intravascular large B-cell lymphoma (IVLBCL), ab-
sence of disease-specic clinical symptoms, and a lack of unied 
diagnostic criteria [2]. Several studies have made attempts to over-
come these challenges. Ponzoni et al. suggested that a random bi-
opsy of uninvolved organs would be a useful conrmatory strat-
egy to distinguish IVLBCL from primary BM DLBCL [3]. Martinez 
et al. proposed the diagnostic criteria of PBML: (1) isolated BM in-
ltration regardless of peripheral blood involvement; (2) no evi-
dence of lymph node, spleen, liver, or other extra marrow involve-
ment on physical examination or imaging studies; (3) absence of 
localized bone tumors; (4) no evidence of bone trabeculae destruc-
tion on BM biopsy; and (5) exclusion of leukemia/lymphoma cases 
that are considered to primarily involve the BM [1]. 
A retrospective review of our patient revealed that his laboratory 
test results strongly correlated with those of primary BM DLBCL: 
(1) meeting all diagnostic criteria except for mild splenomegaly, 
which can be explained by the overall inammatory state; (2) ex-
clusion of central nervous system lymphoma based on CSF cytol-
ogy and brain MRI; and (3) differential diagnosis from IVLBCL 
with negative ndings on lip biopsy. However, the clinicians had 
Fig. 1. Cytomorphology of bone marrow and G-banded karyotype result. (A) Bone marrow aspirate smear showed that the atypical cells were large 
with irregular nuclear contours and cytoplasmic vacuolations. (B) G-banding revealed complex structural and numerical abnormalities; 47~51,Y,-
X,-1,t(1;21)(q25;q22),inv(3)(q21q26.2),del(4)(p13),der(4)t(1;4)(q25;q34),del(6)(q13q23),del(8)(p12),+10,der(11)t(1;11)(p22;q21),+12,-13,t(14;18)
(q21;q22),-15,add(18)(q22),add(20)(q12),+mar1~3[cp16]/46,XY[4]. 
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difculty diagnosing the patient because of atypical manifesta-
tions such as spinal myelitis, lack of cytopenia, and detection of 
autoimmune markers. In this study, we report extremely rare clin-
ical symptoms of primary BM DLBCL and try to draw the atten-
tion of clinicians to this disease entity.
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